Asset profile

PM577 · Prime Medicine (PRME)

Indication: Wilson’s Disease; Alpha-1 Antitrypsin Deficiency
Also known as: PM647

Company

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dy…

Start live analysis of PRME Run 8-agent AI analysis Stock overview

On the calendar

Nov 2028

~ Nov 2028

PRMEPrime Medicine

PM577: Phase 1/Phase 2 trial NCT07748403 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Timeline

Newest first.

Notable

Nov 7, 2025

12:27 PM

PRMEPrime Medicine

Prime Medicine: PM577 WD IND/CTA filing H1’26; PM647 AATD mid-2026

Trial registry changeSEC 8-K

Readiness checklist

Public facts only. We never publish an approval probability.

Updated Sep 14, 2026

Primary endpoint metUnknown

Overall survival significant or trendingUnknown

US / Western patient shareFavourable

2 of 3 sites in the United States

Advisory committee scheduledFavourable

No advisory committee announced

PDUFA date extendedUnknown

Manufacturing inspection recordUnknown

No public inspection record

Company language signals (label discussions)Unknown

Same-class precedentUnknown

Related companies

Each relationship is backed by the filing that stated it.

Bristol Myers Squibb Not US-listedPartner

Cystic Fibrosis Foundation Not US-listedPartner

PRMEPrime MedicineOwner

SEC 8-K Nov 7, 2025

Verify every date against the linked primary source. Informational only. Not investment advice. SimianX is not affiliated with the FDA or the SEC.

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT07748403	Phase 1/2	Recruiting	Nov 1, 2028	42	2 of 3 sites in the United States

More from Prime Medicine

Other drugs and candidates from the same company tracked in this sector.

PM359chronic granulomatous disease (CGD)